Zoetis (MEX:ZTS) Moat Score: 8/10 (As of Jul. 01, 2026)


MEX:ZTS Zoetis Inc MEX:ZTS
69 GF Score
Price MXN1,264.60
GF Value MXN3,415.79
Valuation Significantly Undervalued
View Full Analysis

What is Zoetis Moat Score?

Zoetis MEX:ZTS -3.85% 69 Moat Score is 8 as of Jul. 01, 2026. GuruFocus rates MEX:ZTS with a GF Score™ of 69/100 and a GF Value™ of MXN3,415.79 (Significantly Undervalued). Among 1,031 Drug Manufacturers companies, Zoetis ranks better than 99.71% on this metric.

Zoetis has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

Zoetis has Wide Moat: Zoetis Inc has a robust wide moat due to its leading market position in animal health, strong brand, extensive distribution network, and valuable intellectual property. These factors provide durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zoetis might have Wide Moat - Clear and robust wide moat.

Zoetis  (MEX:ZTS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zoetis Moat Score Related Terms

MEX:ZTS vs UTHR, VTRS, NBIX: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zoetis Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zoetis's Moat Score distribution charts can be found below:

* The bar in red indicates where Zoetis's Moat Score falls into.


MEX:ZTS
69GF Score
Zoetis Inc MEX:ZTS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
Zoetis (MEX:ZTS) has a Moat Score of 8 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Zoetis ranks #3 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Zoetis' Moat Score too high?
Zoetis' current Moat Score is 8. Based on the distribution chart, Zoetis ranks #3 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zoetis has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Moat Score compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #3 out of 1031 companies for Moat Score. This places Zoetis in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Zoetis's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (MEX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN3,415.79, compared to a current price of MXN1,264.60 — trading 63% below its estimated fair value. The current Moat Score is 8. Zoetis' overall GF Score™ is 69/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Zoetis (MEX:ZTS), the current Moat Score is 8 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zoetis (MEX:ZTS) Overvalued in 2026?

Based on GuruFocus' analysis, Zoetis stock appears to be undervalued. The current stock price of MXN1,264.60 is trading 63% below its estimated GF Value™ of MXN3,415.79. GuruFocus considers Zoetis to be Significantly Undervalued.

Key valuation signals for MEX:ZTS:

  • Moat Score: 8
  • GF Value™: MXN3,415.79 vs. price of MXN1,264.60 (63% below fair value)
  • GF Score™: 69/100

No single metric tells the full story. See the MEX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zoetis Business Description

Address 10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
69GF Score

Get the complete analysis for MEX:ZTS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,264.60
Price
MXN3,415.79
GF Value